MUMBAI, India, March 14 -- Intellectual Property India has published a patent application (202517130960 A) filed by Gmp Biotechnology Limited, Hong Kong, on Dec. 23, 2025, for 'tgfb2-irf5 therapeutics for cancer.'
Inventor(s) include Trieu, Vuong.
The application for the patent was published on March 13, under issue no. 11/2026.
According to the abstract released by the Intellectual Property India: "This invention relates to agents, uses, and methods for treating cancer with an agent for suppressing expression of IRF5. Synergistic therapies include agents, uses, and methods for treating cancer with an agent for suppressing expression of IRF5 in combination with agents for suppressing expression of TGF-2. One or more biomarkers can be used to select subjects who benefit from the methods, agents or uses, including IFNGR2, JAK1, and STAT1, as well as TGF-2 and one or more of IRF5, TLR9, FOXP3, CCL22, CREB5, CD8a, CD86, CC14, CD163, ITGAX, and CD11c. The agents and compositions can be used in combination with chemotherapy and other standard of care therapies."
The patent application was internationally filed on June 05, 2024, under International application No.PCT/US2024/032478.
Disclaimer: Curated by HT Syndication.
